A Phase II Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Cotadutide in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Cotadutide (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Acronyms PROXYMO-ADV
- Sponsors AstraZeneca
Most Recent Events
- 10 May 2024 Status changed from active, no longer recruiting to completed.
- 02 May 2024 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 16 Aug 2023 Phase is changed from phase 2/3 to phase 2. New "safety" primary end-points have replaced the previous "therapeutic" ones, and thus "AR" has replaced "TU" as the trial focus. An "immunogenicity" primary end-point is added thus making "PD" also a trial focus.